Tirzepatide 10mg
This dual GIP/GLP-1 receptor agonist has demonstrated superior weight loss and glycemic control compared to selective GLP-1 agonists in landmark clinical trials. Research has shown average weight loss of 20-22.5% at the highest doses, exceeding results from any previously approved obesity medication. Studies have documented unprecedented improvements in HbA1c levels, with over 90% of participants achieving glycemic targets, along with benefits on liver fat and cardiovascular risk factors. The peptide has gained FDA approval for both diabetes and obesity treatment, with many experts considering it a game-changer in metabolic medicine.
This dual GIP/GLP-1 receptor agonist has demonstrated superior weight loss and glycemic control compared to selective GLP-1 agonists in landmark clinical trials. Research has shown average weight loss of 20-22.5% at the highest doses, exceeding results from any previously approved obesity medication. Studies have documented unprecedented improvements in HbA1c levels, with over 90% of participants achieving glycemic targets, along with benefits on liver fat and cardiovascular risk factors. The peptide has gained FDA approval for both diabetes and obesity treatment, with many experts considering it a game-changer in metabolic medicine.
Purity: ≥99% Purity · Formula: C225H348N48O68 · CAS: 2023788-19-2
Fulfilled and shipped direct by MedFit. Orders are confirmed by email, and we follow up on protocol questions ourselves — call the studio any time.